MULTIPLE SPLICE VARIANTS OF THE MU-OPIOID RECEPTOR GENE

Abstract: The present invention encompasses novel splice variant forms of the mu-opioid receptor-1 (MOR-1) and the polynucleotide sequences encoding the MOR-1 splice variants. The invention further encompasses methods of screening for compositions regulating the MOR-1 splice variant activities and the development of therapeutic modalities directed to regulating activity. Regulation of the MOR-1 splice variant activities may impact the physiologic processes of analgesia and weight management.

Description: MULTIPLE SPLICE VARIANTS OF THE MU-OPIOID RECEPTOR GENE CROSS-REFERENCE TO RELATED APPLICATIONS This is a conversion application of US 60/092,980, filed July 16, 1998. STATEMENT OF RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH This work was supported by the government, in part, by grants from the National Institute on Drug Abuse (D A02615 , D A06241 and DA07242) and a Senior Scientist Award (DA00220) to Gavril W. Pasternak and a core grant to Memorial Sloan-Kettering Cancer Center, New York, NY (CA08748). The government may have certain rights to this invention. TECHNICAL FIELD The present invention relates to mu-opioid receptor- 1 (MOR-1) splice variant polypeptides, to DNA sequences encoding the splice variants, to DNA sequences encompassing non-coding region splice variants, to methods of screening compositions for agonists and antagonists of the splice variant receptor activities and to methods of measuring splice variant binding activities. BACKGROUND ART Opiates are drugs derived from opium and include morphine, codeine and a wide variety of semisynthetic opioid congeners derived from them and from thebaine, another component of opium. Opioids include the opiates and all agonists and antagonists with morphine-like activity and naturally occurring endogenous and synthetic opioid peptides. Morphine and other morphine-like opioid agonists are commonly used pharmaceutically to produce analgesia. There are now many compounds with pharmacological properties similar to those produced by morphine, but none has proven to be clinically superior in relieving pain. References to morphine herein will be understood to include morphine-like agonists as well. The effects of morphine on human beings are relatively diverse and include analgesia, drowsiness, changes in mood, respiratory depression, decreased gastrointestinal motility, nausea, vomiting, and alterations of the endocrine and autonomic nervous systems. Pasternak (1993) Clin. Neuropharmacol. 16:1. Doses of morphine need to be tailored based on individual sensitivity to the drug and the pain-sparing needs of the individual. For instance, the typical initial dose of morphine (10mg/70kg) relieves post-operative pain satisfactorily in only two-thirds of patients. Likewise, responses of an individual patient may vary dramatically with different morphine-like drugs and patients may have side effects with one such drug and not another. For example, it is known that some patients who are unable to tolerate morphine may have no problems with an equianalgesic dose of methadone. The mechanisms underlying variations in individual responses to morphine and morphine-like agonists have not been defined. The analgesic effects of morphine are transduced through opioid receptors in the central nervous system (CNS), located at both spinal and multiple supraspinal sites. Morphine and other agonists induce profound analgesia when administered intrathecally or instilled locally into the dorsal horn of the spinal cord. Several mechanisms of action are believed to mediate the inhibition of nociceptive reflexes from reaching higher centers of the brain, including the inhibition of neurotransmitter release by opioid receptors on the termini of primary afferent nerves and post synaptic inhibitory actions on interneurons and on the out-put neurons of the spinothalamic tract. Profound analgesia can also be produced by the instillation of morphine into the third ventricle or within various sites in the midbrain and medulla, most notably the periaqueductal gray matter, the nucleus raphe magnus, and the locus ceruleus. Although the neuronal circuitry responsible has not been defined, these actions produce enhanced activity in the descending aminergic bulbospinal pathways that exert inhibitory effects on the processing of nociceptive information in the spinal cord. Simultaneous administration of morphine at both spinal and supraspinal sites results in a synergized analgesic response, with a ten-fold reduction in the total dose of morphine necessary to produce equivalent analgesia at either site alone. Morphine also exerts effects on the neuroendocrine system. Morphine acts in the hypothalamus to inhibit the release of gonadotropin releasing hormone (GnRH) and corticotropin-releasing factor (CRF), thus decreasing circulating concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), and adrenocorticotropin (ACTH), and β-endorphin. As a result of the decreased concentrations of pituitary trophic hormones, the concentrations of testosterone and cortisol in the plasma decline. The administration of opiates increases the concentration of prolactin (PRL) in plasma, most likely by reducing the dopaminergic inhibition of PRL secretion. With chronic administration, tolerance eventually develops to the effects of morphine on hypothalamic releasing factors. Opiates can interfere with normal gastrointestinal functioning. Morphine decreases both gastric motility and the secretion of hydrochloric acid in the stomach. Morphine may delay passage of gastric contents through the duodenum for as long as 12 hours. Morphine also decreases biliary, pancreatic, and intestinal secretions and delays the digestion of food in the small intestine. Propulsive peristaltic waves in the colon are diminished or abolished after administration of morphine and commonly, constipation occurs. For a detailed review of the physiological effects of morphine, see Reisine and Pasternak (1996) Goodman & Gilman's The pharmacological basis of therapeutics, Ninth Edition (Hardman et al. eds.) McGraw-Hill pp 521-555. Morphine also exerts effects on the immune system. The most firmly established effect of morphine is its ability to inhibit the formation of rosettes by human lymphocytes. The administration of moφhine to animals causes suppression of the cytotoxic activity of natural killer cells and enhances the growth of implanted tumors. These effects appear to be mediated by actions within the CNS. By contrast, β-endorphin enhances the cytotoxic activity of human monocytes in vitro and increases the recruitment of precursor cells into the killer cell population; this peptide also can exert a potent chemotactic effect on these cells. A novel type of receptor (designated e) may be involved. These effects, combined with the synthesis of Proopiomelanocortin (POMC) and preproenkephalin by various cells of the immune system, have stimulated studies of the potential role of opioids in the regulation of immune function. Sibinga and Goldstein (1988) Annu. Rev. Immunol. 6:219. Side effects resulting from the use of morphine range from mild to life- threatening. Morphine causes constriction of the pupil by an excitatory action on the parasympathetic nerve innervating the pupil. Morphine depresses the cough reflex through inhibitory effects on the cough centers in the medulla. Nausea and vomiting occur in some individuals through direct stimulation of the chemoreceptor trigger zone for emesis, in the postrema of the medulla. Therapeutic doses of morphine also result in peripheral vasodilatation, reduced peripheral resistance and an inhibition of baroreceptor reflexes in the cardiovascular system. Additionally, morphine provokes the release of histamines, which can cause hypotension. Morphine depresses respiration, at least in part by direct effects on the brainstem regulatory systems. In humans, death from morphine poisoning is nearly always due to respiratory arrest. Opioid antagonists can produce a dramatic reversal of severe respiratory depression and naloxone is currently the treatment of choice. High doses of morphine and related opioids can produce convulsions that are not always relieved by naloxone. The development of tolerance and physical dependence with repeated use is a characteristic feature of all opiates. Dependence seems to be closely related to tolerance, since treatments that block tolerance to morphine also block dependence. In vivo studies in animal models demonstrate the importance of neurotransmitters and their interactions with opioid pathways in the development of tolerance to morphine. Blockade of glutamate actions by noncompetitive and competitive NMDA (N-methyl-D-aspartate) antagonists blocks morphine tolerance. Trujillo and Akil (1991) Science 251 :85; and Elliott et al. (1994) Pain 56:69. Blockade of the glycine regulatory site on NMDA receptors has similar effects to block tolerance. Kolesnikov et al. (1994) Life Sci. 55:1393. Administering inhibitors of nitric oxide synthase in morphine-tolerant animals reverses tolerance, despite continued opioid administration. Kolesnikov et al. (1993) Proc. Natl. Acad Sci. U.S.A. 90:5162. These studies indicate several important aspects of tolerance and dependence. First, the selective actions of drugs on tolerance and dependence demonstrate that analgesia can be dissociated from these two unwanted actions. Second, the reversal of preexisting tolerance by NMDA antagonists and nitric oxide synthase inhibitors indicates that tolerance is a balance between activation of processes and reversal of those processes. These observations suggest that, by use of selective agonists and/or antagonists, tolerance and dependence in the clinical management of pain can be minimized or disassociated from the therapeutic effects. In addition to morphine, there are a variety of opioids suitable for clinical use. These include, but are not limited to, Levorphanol, Meperidine, Fentanyl, Methadone, Codeine, Propoxyphene and various opioid peptides. Certain opioids are mixed agonists/antagonists and partial agonists. These include pentazocine, nalbuphine, butorphanol, and buprenorphine. The pharmacological effects of levorphanol closely parallel those of morphine although clinical reports suggest that levorphanol produces less nausea. Meperidine exerts its chief pharmacological effects on the central nervous system and the neural elements in the bowel. Meperidine produces a pattern of effects similar but not identical to those described for morphine. In equianalgesic doses, meperidine produces as much sedation, respiratory depression, and euphoria as morphine. The pattern of unwanted side effects that follow the use of meperidine are similar to those observed after equianalgesic doses of morphine, except that constipation and urinary retention are less common. Fentanyl is a synthetic opioid estimated to be 80 times as potent as morphine as an analgesic. High doses of fentanyl can result in severe toxicity and produce side effects including muscular rigidity and respiratory depression. Methadone is an opioid with pharmacological properties similar to morphine. The properties of methadone include effective analgesic activity, efficacy by the oral route and persistent effects with repeated administration. Side effects include detection of miotic and respiratory-depressant effects for more than 24 hours after a single dose, and marked sedation is seen in some patients. Effects on cough, bowel motility, biliary tone and the secretion of pituitary hormones are qualitatively similar to those of morphine. In contrast to morphine, codeine is approximately 60% as effective orally as parenterally, both as an analgesic and as a respiratory depressant. Codeine has an exceptionally low affinity for opioid receptors, and the analgesic effect of codeine is due to its conversion to morphine. However, codeine's antitussive actions probably involve distinct receptors that bind codeine specifically. Propoxyphene produces analgesia and other CNS effects that are similar to those seen with morphine. It is likely that at equianalgesic doses the incidence of side effects such as nausea, anorexia, constipation, abdominal pain, and drowsiness would be similar to those of codeine. Opioid antagonists have therapeutic utility in the treatment of overdosage with opioids. As understanding of the role of endogenous opioid systems in pathophysiological states increases, additional therapeutic indications for these antagonists will emerge. If endogenous opioid systems have not been activated, the pharmacological actions of opioid antagonists depend on whether or not an opioid agonist has been administered previously, the pharmacological profile of that opioid and the degree to which physical dependence on an opioid has developed. The antagonist naloxone produces no discernible subjective effects aside from slight drowsiness. Naltrexone functions similarly, but with higher oral efficacy and a longer duration of action. Currently, naloxone and naltrexone are used clinically to treat opioid overdoses. Their potential utility in the treatment of shock, stroke, spinal cord and brain trauma, and other disorders that may involve mobilization of endogenous opioids remains to be established. The complex interactions of morphine and drugs with mixed agonist/antagonist properties are mediated by multiple classes of opioid receptors. Opioid receptors comprise a family of cell surface proteins, which control a range of biological responses, including pain perception, modulation of affective behavior and motor control, autonomic nervous system regulation and neuroendocrinological function. There are three major classes of opioid receptors in the CNS, designated mu, kappa and delta, which differ in their affinity for various opioid ligands and in their cellular distribution. The different classes of opioid receptors are believed to serve different physiologic functions. Olson et al. (1989) Peptides 10:1253; Lutz and Pfister (1992) J. Receptor Res. 12:267; and Simon (1991) Medicinal Res. Rev. 11 :357. Moφhine produces analgesia primarily through the mu-opioid receptor. However, among the opioid receptors, there is substantial overlap of function as well as of cellular distribution. The mu-opioid receptor mediates the actions of moφhine and moφhine- like opioids, including most clinical analgesics. In addition to moφhine, several highly selective agonists have been developed for mu-opioid receptors, including [D-Ala 2 ,MePhe 4 ,Gly(ol) 5 ]enkephalin (DAMGO), levoφhanol and methadone. Differential sensitivity to antagonists, such as naloxonazine, indicates the pharmacological distinctions between the mu-opioid receptor subtypes, mui and mu 2 . Several of the opioid peptides will also interact with mu-opioid receptors. There are three distinct families of endogenous opioid peptide families, the enkephalins, endoφhins and dynoφhins, where each peptide is derived from a distinct precursor polypeptide. Mu-opioid receptors have a high affinity for the enkephalins as well as β-endoφhin and dynoφhin A. For review, see Reisine and Pasternak (1996). Members of each known class of opioid receptor have been cloned from human cDNA and their predicted amino acid sequences have been determined. Yasuda et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:6736; and Chen et al. (1993) Mol. Pharmacol. 44:8. The opioid receptors belong to a class of transmembrane spanning receptors known as G-protein coupled receptors. G-proteins consist of three tightly associated subunits, alpha, beta and gamma ( 1 : 1 : 1 ) in order of decreasing mass. Following agonist binding to the receptor, a conformational change is transmitted to the G-protein, which causes the G-alpha subunit to exchange a bound GDP for GTP and to dissociate from the beta and gamma subunits. The GTP-bound form of the alpha subunit is typically the effector- modulating moiety. Signal amplification results from the ability of a single receptor to activate many G-protein molecules, and from the stimulation by G- alpha-GTP of many catalytic cycles of the effector. Most opioid receptor-mediated functions appear to be mediated through G-protein interactions. Standifer and Pasternak (1997) Cell Signal. 9:237. Antisense oligodeoxynucleotides directed against various G-protein alpha subunits were shown to differentially block the analgesic actions of the mu-, delta-, and kappa- opioid agonists in mice. Standifer et al. (1996) Mol. Pharmacol. 50:293. The amino acid sequences of the opioid receptors are approximately 65% identical, and they have little sequence similarity to other G-protein-coupled receptors except for somatostatin. Reisine and Bell (1993) Trends Neurosci. 16:506. The regions of highest similarity in sequence are the sequences predicted to lie in the seven transmembrane-spanning regions and the intracellular loops. Regions of amino acid sequence divergence are the amino and carboxy termini and the second and third extracellular loops. Each receptor subtype has a characteristic pattern of expression. Mu- opioid receptor mRNA is present in the periaqueductal gray, spinal trigeminal nucleus, cuneate and gracile nuclei, and thalamus regions of the brain involved in pain perception and associated with moφhine analgesia (Defts et al. (1994) J. Comp. Neurol. 345:46); in nuclei involved in control of respiration, consistent with the ability of moφhine to depress respiration; and in neurons of the area postrema, where moφhine has been shown to cause nausea and induce vomiting. Other consequences of mu-opioid receptor activation include miosis, reduced gastrointestinal motility, and feelings of well-being or euphoria. Pasternak (1993). The pattern of mu-opioid receptor mRNA expression correlates with the brain centers involved in mediating the biological actions of moφhine and mu- selective agonists. Delta-opioid receptor mRNA is found in the dorsal horn of the spinal cord. Kappa! -opioid receptor mRNA is expressed in the hypothalamic regions, which may account for many of the neuroendocrine effects of the kappa selective agonists. Soon after the mu-opioid receptor MOR-1 was cloned (Chen et al. (1993); and Wang et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90:10230), antisense experiments confirmed its involvement with moφhine analgesia. Rossi et al. (1994) Life Sci. 54:375; and Rossi et al. (1995) FEBS Lett. 369:192. Antisense oligonucleotides directed against MOR-1 mRNA blocked the analgesic actions of moφhine in rats, demonstrating that proper translation of the MOR-1 mRNA was essential for modulating moφhine analgesia. Antisense approaches have also demonstrated a relationship between MOR-1 activity and ingestive responses. Administration of antisense oligonucleotides directed against MOR-1 mRNA significantly reduced food and water intake and subsequently, body weight in rats. In recent years, a number of mu-opioid receptor subtypes have been proposed. The first suggestion of mu] and mu 2 receptor subtypes came from a combination of binding and pharmacological studies based on the antagonists naloxonazine and naloxazone. Wolozin and Pasternak (1981) Proc. Natl. Acad. Sci. U.SA. 78:6181; Reisine and Pasternak (1996); and Pasternak (1993). To date, only a single mu receptor gene, MOR-1, has been identified. Min et al. (1994) Proc. Natl. Acad. Sci. U.S.A. 91 :9081; Giros et al. (1995) Life Sci. 56:PL369; and Liang et al. (1995) Brain Res. 679:82. The MOR-1 cDNA consists of exons 1-4, which total 1610 bp in length and encode 398 amino acids. More recently, pharmacological and molecular differences between moφhine and moφhine-6β-glucuronide (M6G) have suggested yet another mu-opioid receptor subtype. Pasternak and Standifer (1995) Trends Pharmacol. Sci. 16:344; Rossi et al. (1995); and Rossi et al. (1996) Neurosci. Lett. 216:1. Antisense oligonucleotides directed against selected exons within the MOR-1 mRNA revealed interesting therapeutic patterns of moφhine and M6G analgesia, with some MOR-1 exons implicated in the analgesic actions of one drug, but not the other. Rossi et al. (1997) J. Pharmacol. Exp. Ther. 281 : 109; and Rossi et al. (1995). Although the two analgesics were known to act through different receptors, the sensitivity of the effect of both analgesics to at least six different MOR-1 antisense probes implied that both receptors were closely associated with MOR-1, raising the possibility of pharmacologically relevant MOR-1 splice variants. Pasternak and Standifer (1995); and Rossi et al. (1995). Alternative splicing has been observed with a number of G-protein-coupled receptors, including somatostatin 2 (Vanetti et al. (1998) FEBS Lett. 311:290), dopamine D2 (Guiramand et al. (1995) J. Biol. Chem. 270:7354), prostaglandin EP3 (Namba et al. (1993) Trends Pharmacol. Sci. 16:246), serotonin receptor subtypes 5-HT 4 and 5-HT (Lucas and Hen. (1995) Trends Pharmacol. Sci. 16:246) and MOR-1. Bare et al. (1994) FEBS Lett. 354:213; and Zimprich et al. (1995) FEBS Lett. 359:142. Several opioid receptor splice variants have been identified and characterized. At least two MOR-1 splice variants are known, the human MOR- 1 A and the rat MOR-lB s. Bare et al. (1994); and Zimprich et al. (1995). The hMOR-lA splice variant consists of exons 1, 2, 3 and a new exon 3a, and was determined to possess ligand binding characteristics similar to the full-length MOR-1. Bare et al. (1994). The rMOR-lB s splice variant consists of exons 1, 2, 3 and a new exon 5, and like hMOR-1 A, differs from MOR-1 only in length and amino acid composition at the carboxy-terminal tail. Zimprich et al. (1995). MOR-lB s has affinity to opioid compounds similar to that of MOR-1, but is much more resistant to agonist-induced desensitization than MOR-1. The C-terminal differences between MOR-1 and MOR-1 A or MOR-1 B s could have effects on receptor coupling or receptor transport and localization. The MOR-1 splice variants are potential targets for the modulation of physiological effects resulting from mu-opioid receptor activity. Availability of polynucleotide sequences of opioid receptor splice variants, and, in the case of splice variants in coding regions, the corresponding polypeptide sequences, will significantly increase the capability to design pharmaceutical compositions, such as analgesics, with enhanced specificity of function. In general, the availability of these polynucleotide and polypeptide sequences will enable efficient screening of candidate compositions. The principle in operation through the screening process is straightforward: natural agonists and antagonists bind to cell-surface receptors and channels to produce physiological effects; certain other molecules can produce physiological effects and act as therapeutic pharmaceutical agents. Thus, the ability of candidate drugs to bind to opioid receptor splice variants can function as an extremely effective screening criterion for the selection of pharmaceutical compositions with desired functional efficacy and specificity. DISCLOSURE OF THE INVENTION The invention encompasses MOR-1 splice variant polypeptides or polypeptide fragments or homologs thereof retaining MOR-1 activity. The invention further encompasses a MOR-1 splice variant polynucleotide, encoding MOR-1 splice variant polypeptides or polypeptide fragments or homologs thereof retaining MOR-1 activity, and noncoding mRNA splice variants and complementary strands thereto. The invention further encompasses a polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of an MOR-1 splice variant polynucleotide where the polynucleotide contains promoter elements. The invention further encompasses methods of screening compositions for an opioid activity by obtaining a control cell that does not express a recombinant or endogenous opioid receptor, obtaining a test cell that expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell and test cell with an amount of an opioid sufficient to exert a physiologic effect, separately measuring the physiologic effect of the composition on the control cell and test cell and comparing the physiologic effect of the composition to the physiologic effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid. The invention further encompasses methods of screening compositions for an opioid activity by obtaining a control polypeptide that is not a recombinant opioid receptor, obtaining a test polypeptide that is a recombinant MOR-1 splice variant polypeptide, contacting a composition with the control polypeptide and the test polypeptide, contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide, measuring the binding of the composition and the opioid, and comparing the test polypeptide binding of the composition to that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid. The invention further encompasses methods of screening compositions for differential or selective opioid activity comprising obtaining a first and second test polypeptide that are MOR-1 splice variant polypeptide fragments and contacting each with a composition, measuring the binding affinity of the composition to the first and second test polypeptides and comparing the binding of the composition and the first test polypeptide to that of the second test polypeptide where differential activity is expressed as a ratio of the two binding affinities. The invention further encompasses a non-human animal in which one or both endogenous MOR-1 alleles has been altered by homologous recombination with an exogenously introduced MOR-1 splice variant polynucleotide. The invention further encompasses a non-human transgenic animal carrying a transgene comprising an MOR-1 splice variant polynucleotide. The invention further encompasses a method for regulating moφhine analgesia in a subject by altering the amount of MOR-1 splice variant polypeptide activity. Activity can be regulated by administering antigen binding fragments, agonists, antagonists or small molecule ligands to a subject in an amount and a duration sufficient to regulate moφhine analgesia. The antigen binding fragment, agonist, antagonist or small molecule ligand is directed to an MOR-1 splice variant polypeptide fragment or MOR-1 splice variant mRNA. The invention further encompasses regulating opioid activity by administering a DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The DNA plasmid vector thereby expresses an mRNA splice variant that may encode an MOR-1 polypeptide in a subject in an amount of and a duration sufficient to regulate moφhine analgesia. Activity can also be regulated by administering an antisense nucleic acid complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene expression in a subject in an amount and a duration sufficient to regulate moφhine analgesia. The invention further encompasses a method for regulating body weight in a subject by altering the amount of MOR-1 splice variant polypeptide activity in the subject. Activity can be regulated by administering antigen binding fragments, agonists, antagonists or small molecule ligands to a subject in an amount and a duration sufficient to regulate body weight. The antigen binding fragment, agonist, antagonist or small molecule ligand is directed to an MOR-1 splice variant polypeptide. Activity can also be regulated by administering to the subject a DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The DNA plasmid vector thereby expresses an MOR-1 polypeptide fragment or MOR-1 splice variant mRNA in the subject in an amount of and a duration sufficient to regulate body weight of the subject. Activity can also be regulated by administering an antisense nucleic acid complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene expression in a subject in an amount and a duration sufficient to regulate body weight of the subject. The invention further encompasses a method for diagnosing an MOR-1 splice variant-associated pharmacological abnormality, comprising measuring the amount of variant activity or tissue distribution thereof in a subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a pharmacologic defect. The invention further encompasses a method for diagnosing an MOR-1 splice variant-associated disorder, comprising measuring the amount of variant activity or tissue distribution thereof in a subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a disorder of the neuroendocrine system. The invention further encompasses antigen-binding fragments specific for the MOR-1 splice variant polypeptides described herein. BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 depicts a schematic diagram of MOR-1 gene structure and alternative splicing. Exons and introns are indicated by boxes and horizontal lines, respectively. The translational start codon and termination codon are AUG and TAA or TAG or TGA. Overlapping genomic clones covering the entire MOR-1 gene are shown by heavy horizontal lines on the top panel. Figure 2 depicts the MOR-1 splice variant polynucleotides. These include: MOR-la; MOR-1 bl; MOR-lc; MOR-ld; MOR-le; MOR-1J; MOR-11; MOR-1F; and clones 3320510, 273015, and 161416. Figure 3 depicts the MOR-1 splice variant polypeptides. These include: MOR-1 C; MOR-1 G; MOR-1D; MOR-1E; MOR-1 H; MOR-11; MOR-1 J; hMOR- 1-610302; MOR-1A; MOR-1 Bl; MOR-1 BII; MOR-1F; and MOR-1. Figure 3 also designates exons and GenBank accession numbers where applicable. Figure 4 compares the amino acid sequences of several MOR-1 splice variant polypeptides predicted from the cDNA clones. All are murine variants except MOR-la and MOR-lb which are human and rat, respectively. In Figure 4, the small solid triangles represent casein kinase phosphorylation sites and the large open triangle represents a protein kinase C phosphorylation site. Figure 5 is a schematic diagram comparing the exons of MOR-11 and MOR-IJ. Figure 6 is a schematic diagram comparing the exons of Clones 161416; 3320510 and 2730510. Figure 7 depicts the results of Northern blots performed on mouse brain using an exon 4 probe and a probe including exons 7/8/9. Figure 8 depicts regional distribution of the MOR-lc, MOR-ld and MOR-le mRNA. In 8 A, RT-PCR was performed on the indicated brain regions using the indicated probes. In 8B, RT-PCR was performed on the indicated brain regions using the indicated probe. Figure 9 depicts immunohistochemical localization of MOR-1 and MOR- 1 C in mouse brain. Sections A and B and Sections C and D were stained with MOR-1 and MOR-1 C antisera respectively. Regions were (A and B) St, striatum; ac, anteriorcommissure; Ac, accumbens; and LS, lateral septum; (c) MD, mediodorsal thalamic nucleus; CM, centromedian thalamic nucleus; DH, dorsal hypothalamic nucleus; LH, lateral hypothalamic nucleus; Ce, central amygdaloid nucleus; Ic, intercalated amygdaloid nucleus; and Me, medial amygdaloid nucleus; and (D) Ar, arcuate nucleus; and ME, median eminence. Figure 10 depicts in vitro translation of MOR-1, MOR-1 C, MOR-1D and MOR-1E. Figure 11 depicts antisense mapping of exons 6, 7, 8 and 9 of MOR-1. The solid bars represent M6G and the stippled bars represent moφhine treatment. BEST MODE FOR CARRYING OUT THE INVENTION In view of the strong pharmacological evidence for distinct mu-opioid receptors, alternative splicing of the MOR-1 gene has been explored further. It has now been determined that the MOR-1 gene is subject to alternative splicing that produces novel splice variant forms of the mRNA and/or receptor. Eleven new exons for the MOR-1 gene have been identified, which combine to yield fifteen novel MOR-1 splice variant polynucleotides. These splice variant polynucleotides and the polypeptides encoded thereby are potential targets for modulating moφhine analgesia and opioid-mediated ingestive responses. The invention further encompasses isolated MOR-1 splice variant polynucleotide sequences indicated in Figure 2. In addition to Figure 2, the polynucleotide sequences can be any sequence of the appropriate genetic code to encode any of the MOR-1 splice variant polypeptides indicated in Figure 3. Preferably, the polynucleotide is at least 15 consecutive nucleotides. A "polynucleotide" is a polymeric form of nucleotides of any length, which contain deoxyribonucleotides, ribonucleotides, and analogs in any combination. Polynucleotides may have three-dimensional structure, and may perform any function, known or unknown. The term "polynucleotide" includes double-, single-stranded, and triple-helical molecules. Unless otherwise specified or required, any embodiment of the invention described herein that is a polynucleotide encompasses both the double stranded form and each of two complementary forms known or predicted to make up the double stranded form of either the DNA, RNA or hybrid molecule. The following are non-limiting examples of polynucleotides: a gene or gene fragment, exons, introns, mRNA, tRNA, rRNA, ribozymes, cDNA, recombinant polynucleotides, branched polynucleotides, plasmids, vectors, isolated DNA of any sequence, isolated RNA of any sequence, nucleic acid probes and primers. A polynucleotide may comprise modified nucleotides, such as methylated nucleotides and nucleotide analogs, uracyl, other sugars and linking groups such as fluororibose and thiolate, and nucleotide branches. The sequence of nucleotides may be further modified after polymerization, such as by conjugation, with a labeling component. Other types of modifications included in this definition are caps, substitution of one or more of the naturally occurring nucleotides with an analog, and introduction of means for attaching the polynucleotide to proteins, metal ions, labeling components, other polynucleotides or solid support. An "isolated" polynucleotide or polypeptide is one that is substantially free of the materials with which it is associated in its native environment. By substantially free, is meant at least 50%, preferably at least 70%, more preferably at least 80%, and even more preferably at least 90% free of these materials. The invention further comprises a complementary strand to the MOR-1 splice variant polynucleotide. The complementary strand can be polymeric and of any length, and can contain deoxyribonucleotides, ribonucleotides, and analogs in any combination. Hybridization reactions can be performed under conditions of different "stringency". Conditions that increase stringency of a hybridization reaction are well known. See for examples, "Molecular Cloning: A Laboratory Manual", second edition (Sambrook et al. 1989). Examples of relevant conditions include (in order of increasing stringency): incubation temperatures of 25°C, 37 °C, 50 °C, and 68 °C; buffer concentrations of 10 x SSC, 6 x SSC, 1 x SSC, 0.1 x SSC (where SSC is 0.15 M NaCl and 15 mM citrate buffer) and their equivalent using other buffer systems; formamide concentrations of 0%, 25%, 50%, and 75%; incubation times from 5 minutes to 24 hours; 1 , 2 or more washing steps; wash incubation times of 1, 2, or 15 minutes; and wash solutions of 6 x SSC, 1 x SSC, 0.1 x SSC, or deionized water. The invention further encompasses polynucleotides encoding functionally equivalent variants and derivatives of the MOR-1 splice variant polypeptides and functionally equivalent fragments thereof which may enhance, decrease or not significantly affect properties of the polypeptides encoded thereby. These functionally equivalent variants, derivatives, and fragments display the ability to retain MOR-1 activity. For instance, changes in a DNA sequence that do not change the encoded amino acid sequence, as well as those that result in conservative substitutions of amino acid residues, one or a few amino acid deletions or additions, and substitution of amino acid residues by amino acid analogs are those which will not significantly affect properties of the encoded polypeptide. Conservative amino acid substitutions are glycine/alanine; valine/isoleucine/leucine; asparagine/glutamine; aspartic acid/glutamic acid; serine/threonine/methionine; lysine/arginine; and phenylalanine/tyrosine/tryptophan. The invention further encompasses the MOR-1 splice variant polynucleotides contained in a vector molecule or an expression vector and operably linked to a promoter element if necessary. A "vector" refers to a recombinant DNA or RNA plasmid or virus that comprises a heterologous polynucleotide to be delivered to a target cell, either in vitro or in vivo. The heterologous polynucleotide may comprise a sequence of interest for puφoses of therapy, and may optionally be in the form of an expression cassette. As used herein, a vector need not be capable of replication in the ultimate target cell or subject. The term includes cloning vectors for translation of a polynucleotide encoding sequence. Also included are viral vectors. The term "recombinant" means a polynucleotide of genomic cDNA, semisynthetic, or synthetic origin which either does not occur in nature or is linked to another polynucleotide in an arrangement not found in nature. "Heterologous" means derived from a genetically distinct entity from the rest of the entity to which it is being compared. For example, a polynucleotide, may be placed by genetic engineering techniques into a plasmid or vector derived from a different source, and is a heterologous polynucleotide. A promoter removed from its native coding sequence and operatively linked to a coding sequence other than the native sequence is a heterologous promoter. The polynucleotides of the invention may comprise additional sequences, such as additional encoding sequences within the same transcription unit, controlling elements such as promoters, ribosome binding sites, polyadenylation sites, additional transcription units under control of the same or a different promoter, sequences that permit cloning, expression, homologous recombination, and transformation of a host cell, and any such construct as may be desirable to provide embodiments of this invention. A "host cell" denotes a prokaryotic or eukaryotic cell that has been genetically altered, or is capable of being genetically altered by administration of an exogenous polynucleotide, such as a recombinant plasmid or vector. When referring to genetically altered cells, the term refers both to the originally altered cell, and to the progeny thereof. Polynucleotides comprising a desired sequence can be inserted into a suitable cloning or expression vector, and the vector in turn can be introduced into a suitable host cell for replication and amplification. Polynucleotides can be introduced into host cells by any means known in the art. The vectors containing the polynucleotides of interest can be introduced into the host cell by any of a number of appropriate means, including direct uptake, endocytosis, transfection, f-mating, electroporation, transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE-dextran, or other substances; microprojectile bombardment; lipofection; and infection (where the vector is infectious, for instance, a retroviral vector). The choice of introducing vectors or polynucleotides will often depend on features of the host cell. Once introduced, the exogenous polynucleotide can be maintained within the cell as a non-integrated vector (such as a plasmid) or integrated into the host cell genome. Amplified DNA can be isolated from the host cell by standard methods. See, e.g., Sambrook et al. (1989). RNA can also be obtained from transformed host cell, or it can be obtained directly from the DNA by using a DNA-dependent RNA polymerase. Expression vectors generally are replicable polynucleotide constructs that contain a polynucleotide encoding the polypeptide of interest. Herein, this means any of the MOR-1 splice variant polypeptides. For expression, one or more translational controlling elements are also usually required, such as ribosome binding sites, translation initiation sites and stop codons. These controlling elements (transcriptional and translational) can be derived from the MOR-1 gene, or heterologous (i.e., derived from other genes or other organisms). A number of expression vectors suitable for expression in eukaryotic cells including yeast, avian, and mammalian cells are well known in the art. One example of an expression vector is pcDNA3 (Invitrogen, San Diego, CA), in which transcription is driven by the cytomegalovirus (CMV) early promoter/enhancer. This vector also contains recognition sites for multiple restriction enzymes for insertion of an MOR-1 splice variant polypeptide of interest. Another example of an expression vector system is the baculovirus/insect system. Cloning and expression vectors typically contain a selectable marker (for example, a gene encoding a protein necessary for the survival or growth of a host cell transformed with the vector), although such a marker gene can be carried on another polynucleotide sequence co-introduced into the host cell. Only those host cells into which a selectable gene has been introduced will grow under selective conditions. Typical selection genes either: (a) confer resistance to antibiotics or other toxins, e.g., ampicillin, neomycin, methotrexate; (b) complement auxotrophic deficiencies; or (c) supply critical nutrients not available for complex media. The choice of the proper marker gene will depend on the host cell, and appropriate genes for different hosts are known in the art. Vectors also typically contain a replication system recognized by the host. Suitable cloning vectors can be constructed according to standard techniques, or selected from a large number of cloning vectors available in the art. While the cloning vector selected may vary according to the host cell intended to be used, useful cloning vectors will generally have the ability to self-replicate, may possess a single target for a particular restriction endonuclease, or may carry marker genes. Suitable examples include plasmids and bacterial viruses, e.g., pUC18, mpl8, mpl9, pBR322, pMB9, ColEl, pCRl, RP4, phage DNAs, and shuttle vectors such as pSA3 and pAT28. These and other cloning vectors are available from commercial vendors such as BioRad, Stratagene, and Invitrogen. The invention further encompasses an isolated polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of the MOR-1 splice variant polynucleotides depicted in (Figure 2) where the polynucleotide contains promoter elements. The MOR-1 splice variant promoter elements, are contained in exons la, lb, and lc or in any combination thereof. Promoter elements can control the level, tissue specificity, inducibility and, in gene clusters, the sequence of transcriptional activation and repression. Promoter elements include but are not limited to, enhancer sequences and repressor sequences. The invention further encompasses non-human animals in which one or both MOR-1 alleles has been altered by homologous recombination with an exogenously introduced nucleic acid. Non-human animals devoid of one or more gene products are generated to determine the "loss-of-function" phenotype associated with the loss of that particular gene product. Herein, the gene product is the MOR-1 gene or splice variants thereof. Phenotypic abnormalities can be present, for instance, in anatomical structures, biochemical and genetic pathways and pharmacological responses. Loss-of-function phenotypic analysis has the potential to reveal the function of the gene product. Methods of homologous recombination with an exogenously introduced nucleic acid are used to inactivate one or more alleles in non-human animals. These methods, as applied to mice and rats, are well known in the art. Capecchi (1989) Science 244:1288. Usually, an exogenous polynucleotide encoding a selectable marker gene, and having sufficient sequence homology to the targeted site of integration at either end of the polynucleotide, is introduced into the genome of embryonic stem cells (ES cells) derived from the inner cell mass of non-human animal blastocysts. Evans and Kaufman (1981) Nature 292:154. Through homologous recombination, the polynucleotide is incoφorated into the genetic locus at the targeted site of integration, replacing the corresponding sequences of the endogenous allele. ES cells are used to generate chimeric animals either by microinjection into, or aggregation with wildtype embryos. Chimeric animals having germ line transmission of the inactivated allele are bred to produce heterozygous, and subsequently, homozygous lines carrying the inactivated allele. Robertson (1991) Biol. Reprod. 44:238. The invention further encompasses non-human transgenic animals carrying a transgenic MOR-1 splice variant polynucleotide. Non-human animals carrying additional copies of the gene of interest are generated to determine the "gain-of-function" phenotype associated with excess of that particular gene product. Herein, the gene product is any of the MOR-1 splice variant polynucleotides. Phenotypic abnormalities can be present, for instance, in anatomical structures, biochemical and genetic pathways and pharmacological responses. Gain-of-function phenotypic analysis has the potential to reveal the function of the gene product. Methods of generating transgenic animals are well known in the art. Jaenisch (1988) Science 240:1468. "Transgenes" are exogenous polynucleotides encoding the gene of interest. Transgenes are introduced into the embryonic genome through microinjection. Alternatively, a transgene encoding the gene of interest and a selectable marker gene is introduced into the ES cell genome through transfection or electroporation. ES cells carrying the transgene are subsequently used to produce animals with multiple copies of the gene of interest. The invention encompasses splice variant polypeptides. The exemplary MOR-1 splice variant polypeptides are composed of the amino acids indicated in (Figure 3). Polypeptide fragments comprising 5 amino acids, more preferably 7 amino acids, more preferably 15 amino acids, more preferably 25 amino acids, more preferably 50 amino acids and more preferably 75 amino acids, which are not the same as the known MOR-1 or MOR-1 variants are claimed herein and encompassed in the term "MOR-1 splice variant polypeptides". The exemplary MOR-1 splice variant polypeptide fragments retain MOR-1 activity. The complete cDNA sequences of MOR-1 C, MOR-1D, and MOR-1E have been deposited in GenBank, numbers AF062752, AF062753, and AF074974 respectively, in satisfaction of the requirements of the Budapest Treaty. The terms "protein", "peptide", "polypeptide" and "polypeptide fragment" are used interchangeably herein to refer to polymers of amino acid residues of any length. The polymer can be linear or branched, it may comprise modified amino acids or amino acid analogs, and it may be interrupted by chemical moieties other than amino acids. The terms also encompass an amino acid polymer that has been modified naturally or by intervention; for example disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation or modification, such as conjugation with a labeling or bioactive component. The MOR-1 splice variant polypeptides retain MOR-1 activity. To "retain MOR-1 activity" is to have a similar level of functional activity as the MOR-1 polypeptide (Figure 3). This activity includes but is not limited to, immunologic and pharmacological activity. The "immunologic activity" is binding to anti-opioid receptor antigen binding fragments. The antigen binding fragments can be any functional antibody, fragment or derivative thereof, including, but not limited to, whole native antibodies, bispecific antibodies, chimeric antibodies, Fab, F(ab')2, single chain V region fragments (scFv), and fusion polypeptides comprising an antigen binding fragment fused to a chemically functional moiety. The "pharmacologic activity" is activation or deactivation of the MOR-1 splice variant polypeptides upon binding of agonists or antagonists. The invention further encompasses MOR-1 splice variant polypeptide homologs. A "homolog" is a polypeptide similar in amino acid sequence to other polypeptides among a single species or, a "homolog" in evolution is a polypeptide similar in amino acid sequence to other polypeptides in different species because they have been inherited from a common ancestor. Preferably, homologs of the present invention are human homologs. Isolation of MOR-1 splice variant human homolog cDNAs can be carried out by any method known in the art. For instance, methods analogous to the isolation of the mouse MOR-1 splice variants described herein (see Example 1). Using primers corresponding to the human MOR-1 gene and a Marathon-Ready human cDNA Library to carry out reactions according to the Marathon cDNA Amplification Kit (Clontech), human MOR-1 splice variants can be obtained. Alternatively, screening of human cDNA libraries with probes corresponding to mouse MOR-1 splice variant sequences can be carried out at reduced stringency to identify human MOR-1 splice variant cDNAs. The invention further encompasses the MOR-1 splice variant polypeptides in a heterodimeric or homodimeric form. A "heterodimer" is a protein made up of more than one kind of polypeptide. A "homodimer" is a protein made up of more than one kind of polypeptide. Pharmaceutical compositions and treatment modalities can be detected by the methods of this invention. The MOR-1 splice variant polypeptide fragments and MOR-1 splice variant nucleic acid sequences can be used in screening for compositions that alter variant activity. Compositions that selectively regulate the MOR-1 splice variant polypeptide fragments or selectively modulate physiological processes can be identified. The invention further encompasses methods of screening compositions for opioid activity by obtaining a control cell that does not express a recombinant opioid receptor and obtaining a test cell that is the same as the control cell except that it expresses a recombinant MOR-1 splice variant polypeptide, contacting the control cell and test cell with an amount of an opioid sufficient to exert a physiologic effect, separately measuring the physiologic effect of the composition on the control cell and test cell and comparing the physiologic effect of the composition to the physiologic effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid. The invention further comprises a method of screening compositions for opioid activity by obtaining a control polypeptide that is not a recombinant opioid receptor and obtaining a test polypeptide that is a recombinant MOR-1 splice variant polypeptide, contacting a composition with the control polypeptide and the test polypeptide, contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide, measuring the binding of the composition and the opioid and comparing the test polypeptide binding of the composition to that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid. The invention further encompasses a method of screening compositions for differential opioid activity by obtaining a first test polypeptide that is an MOR-1 splice variant polypeptide and contacting it with a composition and obtaining a second test polypeptide that is an MOR-1 splice variant polypeptide, measuring the binding of the composition to the first and second test polypeptides, and comparing the binding of the composition and the first test polypeptide to that of the second test polypeptide where differential activity is expressed as a ratio of the two binding affinities. The compositions screened include but are not limited to chemical, synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, media conditioned by cultured eukaryotic cells, natural products and extracts thereof. The opioid can be but is not limited to, moφhine, methadone, etoφhine, levoφhanol, fentanyl, sufentanil, [D-Ala 2 , MePhe 4 , Gly(ol) 5 ]enkephalin (DAMGO), pentazocine, ethylketocyclazocine, bremazocine, spiradoline, [D-Ser 2 , Leu 5 ]enkephalin-Thr 6 (DSLET), Met-enkephalin, Leu-enkephalin, β-endoφhin, dynoφhin A, dynoφhin B, α-neoendoφhin analogs and combinatorial chemistry products thereof. The physiological effect can be measured by any method known in the art such as changes in the levels of neuroendocrine hormones, including, but not limited to prolactin, growth hormone, gonadotropin-releasing hormone, adrenocorticotropin, corticotropin-releasing factor, luteinizing hormone, follicle stimulating hormone, testosterone or cortisol. The physiological effect can also be measured by changes in the levels of neurotransmitters, including but not limited to, acetylcholine or dopamine. Activation of an MOR-1 receptor, and likely, the MOR-1 splice variant polypeptides, stimulates a variety of physiological responses, including analgesia, depression of gastrointestinal motility and respiration, and alterations of the immune, endocrine and autonomic nervous system. Compositions that regulate the activity of the MOR-1 receptor and/or the MOR-1 splice variant polypeptides can elicit responses that have therapeutic effects. The invention is useful in diagnosis, treatment, design and screening of novel reagents. Screening of compounds can result in obtaining those with differential or selective activity. That is, for instance, certain compositions can retain analgesic effects but do not affect peristaltic activity and thus do not cause constipation. Conversely, compositions that lack analgesic effects but affect peristaltic activity would be useful in treating chemotherapy and HIV patients. Other applications relating to the side effects of opiates can be readily envisaged by one of skill in the art. The invention further encompasses a method for regulating moφhine analgesia in a subject by altering the amount of MOR-1 splice variant polypeptide activity in the subject. Activity can be regulated by administering antigen binding fragments, agonists, antagonists or small molecule ligands to a subject in an amount and a duration sufficient to regulate moφhine analgesia. The antigen binding fragment, agonist, antagonist or small molecule ligand is directed to an MOR-1 splice variant. Activity can also be regulated by administering a DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The DNA plasmid vector thereby expresses an MOR-1 splice variant polynucleotide in a subject in an amount and a duration sufficient to regulate moφhine analgesia. Activity can also be regulated by administering an antisense nucleic acid complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene expression in a subject in an amount and a duration sufficient to regulate moφhine analgesia. The invention further encompasses a method for regulating body weight in a subject by altering the amount of MOR-1 splice variant polypeptide activity. Activity can be regulated by administering antigen binding fragments, agonists, antagonists or small molecule ligands to a subject in an amount and a duration sufficient to regulate body weight. The antigen binding fragment, agonist, antagonist or small molecule ligand is directed to or specific for an MOR-1 splice variant polypeptide. Activity can also be regulated by administering to a subject DNA plasmid vector containing an MOR-1 splice variant polynucleotide. The plasmid vector thereby expresses the MOR-1 splice variant polynucleotide in a subject in an amount and a duration sufficient to regulate body weight of the subject. Activity can also be regulated by administering an antisense nucleic acid complementary to an MOR-1 splice variant polynucleotide, thereby blocking gene expression in a subject in an amount and a duration sufficient to regulate body weight. Agonists and antagonists of MOR-1 splice variant polypeptide activity can include but are not limited to, moφhine, methadone, etoφhine, levoφhanol, fentanyl, sufentanil, [D-Ala 2 , MePhe 4 , Gly(ol)5]enkephalin (DAMGO), butoφhanol, naloxone, naltrexone, D-Phe-Cys-Tyr-D-Tφ-Orn-Thr-Pen-Thr-NH 2 (CTOP), diprenoφhine, β-funaltrexamine, naloxonazine, naloφhine, pentazocine, nalbuphine, benzoylhydrazone, bremazocine, ethylketocyclazocine, U50488, U69593, spiradoline, naltrindole, [D-Pen 2 , D-Pen- 5 ]enkephalin (DPDPE), [D- Ala 2 ,Glu 4 ]deltoφhin, [D-Ser 2 ,Leu 5 ]enkephalin-Thr 6 (DSLET), Met-enkephalin, Leu-enkephalin, β-endoφhin, dynoφhin A, dynoφhin B, α-neoendoφhin and derivatives such as those produced by combinatorial chemistry. A "subject" is a vertebrate, preferably a mammal, and more preferably a human. Mammals include but are not limited to humans, farm animals, sport animals, and pets. The invention further encompasses a method for diagnosing an MOR-1 splice variant-associated pharmacological abnormality in a subject, comprising measuring the amount of polypeptide activity or tissue distribution of polypeptide and/or polynucleotide in the subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a pharmacological defect. This disorder can be heritable. The invention further encompasses a method for diagnosing an MOR-1 splice variant-associated disorder of the neuroendocrine system of a subject, comprising measuring the amount of polypeptide activity or tissue distribution of polypeptide and/or polynucleotide thereof in the subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a disorder of the neuroendocrine system. This disorder can be heritable. The invention further encompasses antigen binding fragments specific for an MOR-1 splice variant polypeptide. According to the invention, an MOR-1 splice variant polypeptide can be used as an immunogen to generate antigen binding fragments which immunospecifically bind the immunogen. Production of antigen binding fragments such as polyclonal antibodies can be carried out by any method known in the art. Various host animals can be immunized by injection with the immunogen, including but not limited to rabbits, mice and rats. Various adjuvants can be used to increase the immunological response, depending on the host species, and including but not limited to Freund's (complete or incomplete) adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (Bacille Calmette-Guerin) and Corynebacterium parvum. For preparation of antigen binding fragments such as monoclonal antibodies, any technique which provides for the production of antibody molecules by continuous cell lines in culture can be used. Examples of such techniques include the original hybridoma technique (Kohler and Milstein (1975) Nature 256:495) as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al. (1983) Immunol. Today 4:72), and the EBV hybridoma technique to produce human monoclonal antibodies (Cole et al. (1985) in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Monoclonal antibodies can also be produced in germ-free animals utilizing known technology (PCT/US90/02545). Human antibodies can be obtained using human hybridomas (Cote et al. (1983) Proc. Natl. Acad. Sci. U.S.A. 80:2026), or by transforming human B cells with EBV virus in vitro (Cole et al. (1985)). Techniques developed for the production of "chimeric antibodies" (Morrison et al. (1984) Proc. Natl. Acad. Sci. U.S.A. 81 :6851; Neuberger et al. (1984) Nature 312:604; and Takeda et al. (1985) Nature 314:452) by splicing the genes from a mouse antibody molecule specific for MOR-1 splice variants together with genes from a human antibody of appropriate biological activity can be used. Techniques described for the production of single chain antibodies (U.S. Patent 4,946,778) can be adapted to produce MOR-1 splice variant polypeptide- specific single chain antibodies. Techniques described for the production of Fab expression libraries (Huse et al. (1989) Science 246:1275) can be utilized, allowing rapid and easy identification of monoclonal Fab fragments specific for an MOR-1 splice variant polypeptide. Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(abl), fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(abl) fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments. Single chain V region fragments ("scFv") can also be produced. Single chain V region fragments are made by linking L (light) and/or H (heavy) chain V (variable) regions by using a short linking peptide. Bird et al. (1988) Science 242:423. Any peptide having sufficient flexibility and length can be used as a linker in a scFv. Usually the linker is selected to have little to no immunogenicity. An example of a linking peptide is (GGGGS) 3 , which bridges approximately 3.5 nm between the carboxy terminus of one V region and the amino terminus of another V region. Other linker sequences can also be used, and can provide additional functions, such as for attaching a drug or a solid support. All or any portion of the H or L chain can be used in any combination. Typically, the entire V regions are included in the scFv. For instance, the L chain V region can be linked to the H chain V region. Alternatively, a portion of the L chain V region can be linked to the H chain V region, or a portion thereof. Also contemplated are scFvs in which the H chain V region is from HI 1, and the L chain V region is from another immunoglobulin. It is also possible to construct a biphasic, scFv in which one component is an MOR-1 splice variant polypeptide and another component is a different polypeptide, such as a T cell epitope. The scFvs can be assembled in any order, for example, V H — (linker) — Vr or V L — (linker) — V H - There may be a difference in the level of expression of these two configurations in particular expression systems, in which case one of these forms may be preferred. Tandem scFvs can also be made, such as (X) — (linker) — (X) — (linker) — (X), in which X are MOR-1 splice variant polypeptides, or combinations of MOR-1 splice variant polypeptides with other polypeptides. In another embodiment, single chain antibody polypeptides have no linker polypeptide, or just a short, inflexible linker. Exemplary configurations include V L — V H and VH — V L . The linkage is too short to permit interaction between V L and V H within the chain, and the chains form homodimers with a V L /V H antigen binding site at each end. Such molecules are referred to in the art as "diabodies". ScFvs can be produced either recombinantly or synthetically. For synthetic production of scFv, an automated synthesizer can be used. For recombinant production of scFv, a suitable plasmid containing a polynucleotide that encodes the scFv can be introduced into a suitable host cell, either eukaryotic, such as yeast, plant, insect or mammalian cells, or prokaryotic, such as Escherichia coli, and the protein expressed by the polynucleotide can be isolated using standard protein purification techniques. A particularly useful system for the production of scFvs is plasmid pET- 22b(+) (Novagen, Madison, WI) in E. coli. pET-22b(+) contains a nickel ion binding domain consisting of 6 sequential histidine residues, which allows the expressed protein to be purified on a suitable affinity resin. Another example of a suitable vector is pcDNA3 (Invitrogen, San Diego, CA), described above. The following examples are provided to illustrate but not limit the claimed invention. EXAMPLE 1 Identification of MOR-1 C, MOR-1D, and MOR-1E cDNA Sequences The cDNA clones of the MOR-1 splice variants MOR-lc, MOR-ld, and MOR-le were isolated using 3'- Rapid Amplification of cDNA Ends (RACE) and Reverse Transcription Polymerase Chain Reaction (RT-PCR). First, standard PCR reactions were performed using a Marathon cDNA Amplification Kit (Clontech) and a Marathon-Ready mouse cDNA Library. A sense primer located at the 3'-end of exon 3, nucleotide position 1338 to 1359 of the mouse mu-opioid receptor, and an antisense adapter primer were used to PCR amplify a mouse brain cDNA template. The PCR products were separated on an agarose gel. Multiple bands were amplified and each band was excised. Individual bands were amplified using a second set of nested primers, including a sense primer located at position 1394-1412 of the MOR-1 receptor, and an antisense adapter primer. The resulting PCR fragments were then subcloned into Bluescript plasmids and sequenced. The sequence of one clone, 110222, was approximately 500 bp in length and failed to align with the sequence of MOR-1 (GenBank Accession #U26915). Clone 110222 contained partial 3' MOR-1 exon 3 sequences followed by a novel sequence. The new sequence was 454 bp long and open reading frame analysis predicted 7 amino acids beyond exon 3 followed by a termination codon and a 3 ' untranslated region (UTR). To obtain full length cDNA clones of the 110222 variant, a sense primer corresponding to the 5' UTR of MOR-1, nucleotide position 217 to 240, and an antisense primer corresponding to the 3' UTR of the new sequence, antisense primer A (5' CCA CAC TGC TCA CCA GCT CAT CCC 3'), were used in RT- PCR amplification of mouse brain RNA. Three fragments of approximately 1.3, 1.4 and 1.5 kb in length, respectively, were obtained, subcloned into pCRII-ToPo plasmid (Invitrogen, Carlsbad, CA) and sequenced in both directions. The three clones obtained are named MOR-lc, MOR-ld and MOR-le. Through sequence analysis it was determined that all three clones contain the same coding exons 1, 2 and 3 from MOR-1, with novel sequences beginning downstream of exon 3. In addition, MOR-lc and MOR-le contain an alternate exon. MOR-ld aligned with the original clone 110222. MOR-lc contains an 89 bp insertion between exon 3 and the 454 bp sequence identified in MOR-ld. MOR-le has a 209 bp insertion between exon 3 and the 454 bp sequence identified in MOR-ld, making it the longest novel sequence. The last 89 bp in this insertion are identical to the 89 bp sequence found in MOR-lc. (Figure 2). The three new variants are derived from combinations of five newly discovered exons located downstream from the original MOR-1 exon 4. Exon 6 is 120 bp, exon 7 is 89 bp, exon 8 is 66 bp, and exon 9 is the longest, 388 bp. MOR- ld encodes exons 1, 2, 3, 8 and 9 (Figure 2), MOR-lc encodes exons 1, 2, 3, 7, 8 and 9 (Figure 2), and MOR-le encodes exons 1, 2, 3, 6, 7, 8, and 9 (Figure 2). All of the new exons have flanking sequences that are consistent with consensus splice junctions. Thus, the MOR-1 gene consists of nine exons spanning at least 200 kb. This is depicted in Figure 1. The predicted amino acid sequences for these new variants differ from MOR-1 and from each other. MOR-1 has 12 predicted amino acids. MOR-ld has only 7 predicted amino acids. Although MOR-lc contains the same new sequence found in MOR-ld, the 89 bp insertion produces a reading-frame shift. As a result, open reading frame analysis of MOR-lc predicts 52 amino acids, which do not include the amino acid sequence from MOR-ld. The termination codon in MOR-le is found in exon 6, therefore exons 7, 8 and 9 are not translated and MOR-le is translated into only 15 amino acids. The AA sequences of the MOR-1 splice variants predicted from the cDNA clones are compared in Figure 4. Partial human mu opioid splice variant sequences were obtained using an RT-PCR approach. We amplified a cDNA fragment from human brain which contained an alternatively spliced exon 4 of human MOR-1 gene. In the PCR reaction, template was the first-strand cDNA reverse-transcribed from human brain mRNA, and a sense primer derived from exon 3 of the human MOR-1 gene, and an antisense primer derived from exon 7 of the mouse MOR-1 gene (5'TGT CCA TGC AAC TCT TGC AGG GTT TTT CAA CAT GAG TCG GAG AAG GAT3'). Sequence analysis of the fragment indicated that it contains the human exon 3 sequences from the sense primer to the end of exon 3 and a 104 bp new sequence between exon 3 and the mouse antisense primer. (Figure 2). Translation of the sequence from exon 3 into the new sequence indicates that it encodes 34 AA with no homology to any mouse variants. (Figure 3). However it does not contain a stop codon, which suggests there is more downstream exon sequence. The new sequence has been mapped, in a human genomic BAC clone to lOkb downstream of human exon 4. Cloning strategy for MOR- II and MOR-1J A sense primer designed from exon 3 (5'GGG AAC ACC CCT CCA CGG3') and an antisense primer from exon 5a (5'GGT GTG CTT CTC CCA GTT CTG TGT3') were used in RT-PCR of mouse brain RNA. Two fragments of approximately 0.2 and 0.7 kb in length, respectively, were obtained, subcloned into pcRIIToPo plasmid and sequenced. Sequence analysis indicates that the 0.2 kb fragment, MOR- II, contains exons 3 and 5a except that there is a 94 kb insertion, exon 11, between exons 3 and 5 a. (Figure 2). Exon 11 only encodes 2AA (CV). The 0.7 kb fragment, MOR-1 J, also contains exons 3 and 5a sequences, but there is a 617 bp insertion, exon 12, between exons 3 and 5a. Exon 12 encodes 7 A A. (Figures 3 and 5). Cloning strategy for 161416 (containing exon lb) A sense primer designed from exon la (5 'CCT CCA GGC TCA TTT CAG AGA GA3') and an antisense primer from exon 1 (5'CAG GAA GTT TCC AAA GAG GCC C3 ') were used in RT-PCR of mouse brain RNA. The PCR fragment obtained was subcloned into pcRIIToPo plasmid and sequenced. Sequence analysis of the fragment indicates that there is a 127 bp insertion sequence, exon lb, between exons la and 1. (Figure 2). Cloning strategy for 2730510 and 3320510 (containing exon 1 c) The sense primer above (exon la) and an antisense primer from exon 2 (5'GGG CAG GTG GTA GTG GCT AAG GC3') were used in RT-PCR of mouse brain RNA. Two fragments of approximately 0.26 and 0.6 kb in length, respectively, were obtained, subcloned into pcRIIToPo plasmid and sequenced. Sequence analysis indicated that the 0.26 kb fragment clone 2730510 contains both exon la and exon 2 sequences, except that there is a 129 bp insertion, exon lc, between exons la and 2. The clone 3320510, however, contains exons la, lc, 1 and 2. (Figures 2 and 6). Cloning strategy for mMOR- 1 Bl and mMOR- 1 BII Mouse exon 5 a sequence was obtained by sequencing mouse Genome BAC clone A using primers derived from rat MOR- IB sequences (Zimprich et al. (1995)). Then an antisense primer designed from the mouse exon 5a and a sense primer from the 5' UTR of MOR-1 nucleotide position 217 to 240 were used in RT-PCR amplification of mouse brain RNA. Two fragments of approximately 1.3 and 2.0 kb in length, respectively, were obtained, subcloned into PCRII-ToPo plasmid and sequenced. Sequence analysis of the fragments indicated that similar to rat MOR- IB, the 1.3 kb fragment contains exons 1, 2, 3 and 5a which encodes 5 AA (KIDLE). However, the 2.0 kb fragment had the same exons 1, 2, 3 and 5a, except that there is a 699 bp insertion sequence, exon 5b, between exons 3 and 5a. Exon 5b encodes 23 AA KLLMWRAMPTFKRHLAIMLSLDN. (Fig.s 2 and 3). Cloning strategy for mMOR- 1 A First, we obtained mouse exon 3 a sequence by sequencing mouse Genomic BAC clone A with exon 3 primers. The full length cDNA of mMOR- 1 A was then obtained by RT-PCR using the first-strand cDNA reverse-transcribed from mouse brain total RNA as template. A sense primer corresponding to the 5' UTR of MOR- 1 , nucleotide position 217 to 240, and an antisense primer corresponding to the 3' UTR of exon 3a (5'GAT CAG AAT TTG GTG CCC TAC TCC CTC TCT3') were used in PCR. The PCR fragment was subcloned into pcRIIToPo plasmid and sequenced. Sequence analysis of the fragment showed that exon splice pattern was exons 1, 2, 3 and 3a which encodes 4AA (VCAF). (Figures 2 and 3). EXAMPLE 2 Mapping of the MOR-1 Gene to Mouse Chromosome 10 In order to obtain genomic clones containing the full-length MOR-1 gene, two mouse genomic BAC libraries (Genome Systems, St. Louis, MI and Research Genetics, Huntsville, AL) and a mouse genomic PI library (Genome Systems) were screened using either PCR or standard hybridization methods. Initially, BAC clone A (-75 kb), was obtained from the Genome Systems BAC library using MOR-1 exon 4 primers for PCR amplification. BAC clone A contained only MOR-1 exons 1, 2, 3 and 4. Since no positive clones were obtained by screening the BAC library with a probe corresponding to exons 8 and 9, we screened the PI library with this probe and obtained PI clone A (-100 kb in length). PI clone A contained exon 8 and 9 sequences, however, it shared no overlapping sequences with either BAC clone A or exons 6 and 7. To identify a clone containing these insertions, a second mouse BAC library (Research Genetics, Inc.) was screened by hybridization with a probe corresponding to the insertional sequences (exon 6). One new clone, BAC clone B (-120 kb) contained exons 4, 6 and 7. Alignment of the three genomic clones predicted an MOR-1 gene of approximately 230 kb . Chromosomal localization of PI clone A was carried out using FISH methods developed by Genome Systems, Inc. PI clone A was labeled with digoxigenin dUTP and hybridized to metaphase chromosomes derived from a mouse embryo fibroblast cell line. Specific hybridization signals were detected by incubating the hybridized slides in fluoresceinated anti-digoxigenin antibodies followed by counterstaining with DAPI. The initial experiment resulted in specific labeling of the proximal portion of a medium sized chromosome, identified as chromosome 10 on the basis of DAPI staining. Cohybridization of a specific probe for the telomeric region of chromosome 10 with the PI clone A demonstrated conclusively that the PI clone A was located immediately adjacent to the heterochromatic euchromatic boundary of chromosome 10, an area corresponding to band 10A2. A total of 80 metaphase cells were analyzed with 68 exhibiting specific labeling. Genome Systems Inc. used inteφhase FISH analysis (van den Engh et al. (1992) Science 257:1410) to estimate the physical distance between the BAC clone A and the PI clone A. The distance between the BAC clone A and the PI clone A estimated was approximately 250 kb, with a possible error of approximately 30%. This was in agreement with the size derived from the overlapping genomic clones, which predicted an MOR-1 gene of approximately 230 kb. (Figure 2) EXAMPLE 3 Expression Patterns of the MOR-1 Variants To determine the lengths of the mRNA transcripts encoding the MOR-1 variants, Northern blot analysis was performed as described previously by Pan et al. (1994). Total RNA was isolated from mouse brain using the guanidinium thiocyanate phenol-chloroform extraction method. Samples of total brain RNA (50 μg) were separated on a 0.8%> formaldehyde agarose gel, and transferred to a Gene Plus membrane. The membrane was hybridized with 32 P-labeled fragments corresponding to sequences from exons 7, 8, and 9 of the MOR-1 variants. Northern analysis of the variants indicates mRNA transcripts ranging in size from approximately 6 to 9 kb (Figure 7). A probe specific for exon 7 would detect only MOR-lc and MOR-le. A probe specific for exon 6 fails to detect MOR-le mRNA The regional pattern of MOR-1 variant mRNA expression was determined using RT-PCR analysis. Total RNA was extracted from multiple mouse brain regions as described above and reverse-transcribed with Super Script II Reverse Transcriptase (GIBCO) in the presence of random hexamers. RNA loading was estimated by comparison to a parallel PCR reaction using β 2 -microglobulin primers (ClonTech). The agarose gel was stained with ethidium bromide and photographed by a Kodak DC 120 Digital Camera and Imagine System. Three major bands were amplified and the predicted sizes of the PCR products for MOR- 1 c, MOR- 1 d and MOR- 1 e are 246 bp, 157 bp and 366 bp, respectively. Each band was extracted from the agarose gel, subcloned into a pCRII-ToPo plasmid and sequenced, confirming that the amplification products corresponded to their respective variants. MOR-lc is the predominant isoform in all of the brain regions examined, but the relative expression of the other variants varied widely (Figure 8 A). MOR- 1 was expressed in all regions (Figure 8B). MOR-le and MOR-ld display differential patterns of expression. In the thalamus, there is little evidence for either MOR-ld or MOR-le expression. MOR-lc mRNA is predominant in the spinal cord, with lower levels of MOR-le expression and no observable MOR-ld expression present. In contrast, the periaqueductal gray (PAG) and striarum, all three of the variants are detected, with the highest levels of expression displayed by MOR-lc, followed by MOR-le and then MOR-ld. The cortex has comparably higher levels of MOR-ld expression than MOR-le expression, as do the cerebellum and brainstem. Regional distribution of MOR- 1 c was analyzed using a polyclonal antibody generated against a unique amino acid sequence in this variant. Mouse brains were sectioned and immunostaining for MOR-1 and MOR-lc determined as described. Abbadie et al. (1996) Neuroscience 70:201; Abbadie et al. (1999) Proc. Natl. Acad. Sci. U.S.A. 96:260); and Abbadie et al. (1999) submitted. Sections A and B and sections C and D were stained with MOR-1 and MOR-1C antisera, respectively. Regions were as follows: A and B) St, striatum; ac, anterior commissure; Ac, accumbens; LS, lateral septum; C) MD, mediodorsal thalamic nucleus; CM, centromedial thalamic nucleus; DH, dorsal hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus; LH, lateral hypothalamic nucleus; Ce, central amygdaloid nucleus; Ic, intercalated amygdaloid nucleus; Me, medial amygdaloid nucleus; D) Ar, arcuate nucleus; ME, median eminence. Western blotting showed that the polyclonal antibody recognized MOR-1C, but not MOR-1 obtained from transfected cells. Sections through the striatum (Figure 9A and B) demonstrate marked differences between MOR-1 and MOR-lc. MOR-1 immunolabeling is observed in patches in the striatum, as well as in the subcallosal streak. Dense areas of labeling are also seen in the nucleus accumbens. MOR-lc antiserum fails to label these areas. There is MOR-lc immunoreactivity in regions of the lateral septum which have minimal staining with MOR-1 antiserum. The hypothalamus has significant differences between the two antisera (Figure 9C and D). While there is some MOR-1 staining, MOR-lc immunoreactivity is far more intense in the arcuate nucleus and median eminence. Additional studies show intense MOR-lc immunoreactivity in the trigeminal tract and the dorsal horn of the spinal cord, as well as the PAG. EXAMPLE 4 Binding Activity of the Variants The cDNA fragments containing the full length MOR-1 or the MOR-1 variants in pCRII-ToPo were subcloned into pcDNA3.1 (Invitrogen, Carlsbad, CA), a mammalian expression vector. Synthesis of MOR-1 C, MOR- ID, and MOR- IE full-length proteins was carried out in vitro using a TNT coupled reticulocyte lysate kit (Promega, Madison, WI). MOR-l/pcDNA3, MOR- lc/pcDNA3, and MOR-ld/pcDNA3 plasmids were incubated with T7 RNA polymerase and reticulocyte lysate in the presence of 0.04 mCi of [ 35 S]methionine (>1000 Ci/mmol; DuPont-NEN, Boston, MA) at 30°C for 1 hour. The translation products were separated by a 12.5% SDS-PAGE gel, which was treated with Amplify (Amersham Life Science), dried and exposed on Kodak BioMax MR film. The MOR- ID and MOR- IE variants had molecular weights similar to that of MOR-1, while the size of MOR-1 C was larger than the others, as expected based upon the predicted amino acid sequences (Figures 3 and 10). CHO cells were stably transfected with plasmids MOR-l/pcDNA3, MOR- lc/pcDNA3, MOR-ld/pcDNA3 or MOR-le/pcDNA3 using LipofectAMLNE reagents (GIBCO, Gaithersburg, MD). Stable transformants were subcloned two weeks after selection with G418 and positive clones were identified using a 3 H- DAMGO binding assay. To examine opioid binding, membranes were prepared from pcDNA3 stable transformants as described previously by Pan et al. (1994); and Pan et al. (1996). 3 H-DAMGO binding was performed at 25°C for 60 minutes in 50 mM potassium phosphate buffer, pH 7.4, containing 5 mM magnesium sulfate. Specific binding was defined as the difference between total binding and nonspecific binding, as indicated by levalloφhan (1 μM). K D and KT values were calculated by nonlinear regression analysis (Prism, Graph Pad Software). Protein concentrations were determined against bovine serum albumin as the standard curve. Lowry et al. (1951) J. Biol. Chem. 193:265. Saturation studies were performed and the binding parameters established by nonlinear regression analysis. 3 H-DAMGO binding was examined in stable lines expressing either MOR- 1 or MOR- 1 C . In saturation studies 3 H-DAMGO displays high affinity for all the variants (Table 1). Indeed, the new variants bind 3 H-DAMGO with higher affinities than MOR-1. Results are reported as the means ± s.e.m of at least 3 independent determinations. Table 1 Competition studies were performed using at least three concentrations of the indicated competitor. 3 H-DAMGO binding was performed in stable transfectants containing the indicated cDNA's. Analysis of variance was performed to determine whether there were differences among the various clones for each competitor, followed by Tukey's post hoc analysis. In competition studies, mu ligands such as moφhine, DAMGO, M6G and the endoφhins bind competitively while the kappa ! opioid U50,488H and the delta opioid ligand [D-Pen 2 ,D-Pen 5 ]enkephalin (DPDPE) are ineffective. However, the binding selectivity profiles among the variants are significantly different. For example, moφhine competes for binding to the MOR- ID variant over 3-fold more potently than against MOR-1 itself (p<0.05). Similarly, the opioid peptide DSLET is twice as potent against binding to the MOR- ID variant than MOR-1 (p<0.05). The most dramatic differences in potency are seen with the endogenous opioids dynoφhin A (p<0.0001) and β-endoφhin (p<0.0003). The MOR- ID variant has the highest affinity for both dynoφhin A and β- endoφhin. MOR- IE also has a significantly higher affinity for β-endoφhin than MOR-1. Dynoφhin A has significantly higher affinity for MOR-1C and MOR- ID than either MOR-1 or MOR- IE. Through competition studies all of the variants have been classified within the mu opioid receptor family (Table 2). Results are reported as the means ± s.e.m. of at least 3 independent determinations. Table 2: Selectivity of MOR-1 and MOR-1C in the receptor binding assay EXAMPLE 5 Functional Significance of the Variants 10 Antisense mapping was used to explore the functional significance of these new variants. Pasternak and Standifer (1995); and Standifer et al. (1994). This method has been used extensively to correlate opioid pharmacology with the function of the MOR-1 receptor. Rossi et al. (1994); Rossi et al. (1995); Rossi et al. (1995); and Kolesnikov et al. (1996). Groups of mice (n > 20) received 15 antisense oligodeoxynucleotides corresponding to specific MOR- 1 , MOR- 1 c, MOR-ld, or MOR-le exons daily for five days. Following administration of the antisense probes, analgesia was assessed by the radiant heat tailflick assay. Rossi et al. (1996); and Rossi et al. (1995). This assay was performed by exposing tails to a light source and determining the baseline latency (typically between 2 and 3 sec). Analgesia was indicated when doubling of the baseline latency occurred. Significance between groups was assessed using the Fisher Exact Test. The remaining activity of the variants was measured following administration of the antisense probes in the presence of both moφhine and M6G analgesia (Figure 11), two mu drugs whose actions have been distinguished using antisense approaches. Rossi et al. (1994); Rossi et al. (1995); and Rossi et al., (1995). All four antisense probes significantly lowered moφhine analgesia (Figure 11). A mismatch control probe targeted against exon 7 was inactive, confirming the specificity of the response. In contrast to their significant blockade of moφhine analgesia, none of the antisense probes significantly lowered M6G analgesia. Thus, these exons are not a component of the postulated M6G receptor. The reduction in moφhine analgesia produced by the antisense probes implies that each of the variant mRNAs, and ultimately the receptor(s) which they encode, are involved in mediating moφhine analgesia. All references cited herein, are hereby incoφorated herein. Although the foregoing invention has been described in some detail, by way of illustration and example for the puφoses of clarity and understanding, it will be apparent to those skilled in the art that certain changes and modifications can be practiced. Therefore, the description and examples should not be construed as limiting the scope of the invention, which is delineated by the appended claims.

Claims: CLAIMS 1. An isolated MOR-1 splice variant polypeptide where the MOR-1 polypeptide fragments are not the same as a polypeptide derived from MOR-1 as depicted in Figure 3. 2. The polypeptide according to claim 1 , where the activity is selected from the group consisting of functional, immunologic, or pharmacological activity. 3. The immunologic activity according to claim 2, where the activity is binding to anti-opioid receptor antigen binding fragments selected from the group consisting of whole native antibodies, bispecific antibodies, chimeric antibodies, Fab, F(ab')2, single chain V region fragments (scFv), and fusion polypeptides comprising an antigen-binding fragment fused to a chemically functional moiety. 4. The pharmacologic activity according to claim 2, where the activity is activation or deactivation of the MOR-1 splice variant polypeptide fragment upon binding of agonists and antagonists. 5. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1C as depicted in Figure 3. 6. The polypeptide according to claim 5, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 7, 8 and 9 as depicted in Figure 2. 7. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- ID as depicted in Figure 3. 8. The polypeptide according to claim 7, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 8 as depicted in Figure 2. 9. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IE as depicted in Figure 3. 10. The polypeptide according to claim 9, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 6 as depicted in Figure 2. 11. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IF as depicted in Figure 3. 12. The polypeptide according to claim 11, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 10 as depicted in Figure 2. 13. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1 A as depicted in Figure 3. 14. The polypeptide according to claim 13, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 3a as depicted in Figure 2. 15. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1H as depicted in Figure 3. 16. The polypeptide according to claim 15, where the MOR-1 polypeptide comprises amino acid residues encoded by exons la, 7, 8 and 9 as depicted in Figure 2. 17. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IB II as depicted in Figure 3. 18. The polypeptide according to claim 17, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 5 a and 5b as depicted in Figure 2. 19. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IB I as depicted in Figure 3. 20. The polypeptide according to claim 19, where the MOR-1 polypeptide comprises amino acid residues encoded by exons as depicted in 5a Figure 2. 21. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- II as depicted in Figure 3. 22. The polypeptide according to claim 21, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 11 as depicted in Figure 2. 23. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1 J as depicted in Figure 3. 24. The polypeptide according to claim 23, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 12 as depicted in Figure 2. 25. The polypeptide according to claim 1, where the MOR-1 polypeptide comprises amino acid residues encoded by human 610302 as depicted in Figure 3. 26 The polypeptide according to claim 25, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 3 and 5 as depicted in Figure 2. 27. The polypeptide, according to claim 1, where the homolog is a human homolog. 28. The polypeptide according to claim 1, consisting of a heterodimeric or homodimeric composition. 29. An isolated polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of the MOR-1 polynucleotide fragment depicted in Figure 2 where the polynucleotide is not the same as a polynucleotide derived from MOR-1 as depicted in Figure 2. 30. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 C as depicted in Figure 2. 31. The polynucleotide according to claim 30, where the nucleotide fragment comprises exons 7, 8, and 9 as depicted in Figure 2. 32. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- ID as depicted in Figure 2. 33. The polynucleotide according to claim 32, where the nucleotide fragment comprises exons 8 and 9 as depicted in Figure 2. 34. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- IE as depicted in Figure 2. 35. The polynucleotide according to claim 34, where the nucleotide fragment comprises exons 6, 7, 8, and 9 as depicted in Figure 2. 36. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- IF (Figure). 37. The polynucleotide according to claim 36, where the nucleotide fragment comprises exons 10, 6, 7, 8, and 9 as depicted in Figure 2. 38. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 G as depicted in Figure 2. 39. The polynucleotide according to claim 38, where the nucleotide fragment comprises exon la as depicted in Figure 2. 40. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 H as depicted in Figure 2. 41. The polynucleotide according to claim 40, where the nucleotide fragment comprises exons la, 7, 8 and 9 as depicted in Figure 2. 42. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- IB II as depicted in Figure 2. 43. The polynucleotide according to claim 42, where the nucleotide fragment comprises exons 5a and 5b as depicted in Figure 2. 44. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 A as depicted in Figure 2. 45. The polynucleotide according to claim 44, where the nucleotide fragment comprises exon 3a as depicted in Figure 2. 46. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- IB I as depicted in Figure 2. 47. The polynucleotide according to claim 46, where the nucleotide fragment comprises exon 5a as depicted in Figure 2. 48. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR- II as depicted in Figure 2. 49. The polynucleotide according to claim 48, where the nucleotide fragment comprises exons 5a and 11 as depicted in Figure 2. 50. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-IJ as depicted in Figure 2. 51. The polynucleotide according to claim 50, where the nucleotide fragment comprises exons 5 a and 12 as depicted in Figure 2. 52. The polynucleotide according to claim 29, where the nucleotide fragment comprises at least 15 consecutive nucleotides of human 610302 as depicted in Figure 2. 53. The polynucleotide according to claim 52, where the nucleotide fragment comprises exons 3 and 4c as depicted in Figure 2. 54. A polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, of at least 15 consecutive nucleotides encoding the isolated MOR-1 polypeptide fragment. 55. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-IC as depicted in Figure 3. 56. The polynucleotide according to claim 55, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 7, 8 and 9 as depicted in Figure 3. 57. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- ID as depicted in Figure 3. 58. The polynucleotide according to claim 57, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 8 as depicted in Figure 3. 59. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IE as depicted in Figure 3. 60. The polynucleotide according to claim 59, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 6 as depicted in Figure 3. 61. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IF as depicted in Figure 3. 62. The polynucleotide according to claim 61, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 10 as depicted in Figure 3. 63. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1 A as depicted in Figure 3. 64. The polynucleotide according to claim 63, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 3 a as depicted in Figure 3. 65. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR-1H as depicted in Figure 3. 66. The polynucleotide according to claim 65, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 7, 8, and 9 as depicted in Figure 3. 67. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IB II as depicted in Figure 3. 68. The polynucleotide according to claim 67, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 5a and 5b as depicted in Figure 3. 69. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IB I as depicted in Figure 3. 70. The polynucleotide according to claim 69, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 5a as depicted in Figure 3. 71. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- II as depicted in Figure 3. 72. The polynucleotide according to claim 71, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 11 as depicted in Figure 3. 73. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by MOR- IB as depicted in Figure 3. 74. The polynucleotide according to claim 73, where the MOR-1 polypeptide comprises amino acid residues encoded by exon 12 as depicted in Figure 3. 75. The polynucleotide according to claim 54, where the MOR-1 polypeptide comprises amino acid residues encoded by human 610302 as depicted in Figure 3. 76. The polynucleotide according to claim 75, where the MOR-1 polypeptide comprises amino acid residues encoded by exons 3 and 5 as depicted in Figure 3. 77. The nucleic acid of claim 29 or 54 contained in a vector molecule. 78. The nucleic acid of claim 29 or 54 contained in an expression vector and operably linked to a promoter element. 79. An isolated polynucleotide, or a complementary strand thereto that hybridizes under stringent conditions, comprising at least 15 consecutive nucleotides of the MOR-1 polynucleotide fragment depicted in Figure 2 where the polynucleotide contains promoter elements. 80. The polynucleotide according to claim 79, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 G as depicted in Figure 2. 81. The polynucleotide according to claim 80, where the nucleotide fragment comprises exon la as depicted in Figure 2. 82. The polynucleotide according to claim 79, where the nucleotide fragment comprises at least 15 consecutive nucleotides of MOR-1 H as depicted in Figure 2. 83. The polynucleotide according to claim 82, where the nucleotide fragment comprises exon la as depicted in Figure 2. 84. The polynucleotide according to claim 79, where the nucleotide fragment comprises at least 15 consecutive nucleotides of 3320510 as depicted in Figure 2. 85. The polynucleotide according to claim 84, where the nucleotide fragment comprises exons la and lc as depicted in Figure 2. 86. The polynucleotide according to claim 79, where the nucleotide fragment comprises at least 15 consecutive nucleotides of 2730510 as depicted in Figure 2. 87. The polynucleotide according to claim 86, where the nucleotide fragment comprises exons la and lb as depicted in Figure 2. 88. A method of screening compositions for opioid activity comprising the steps of a) obtaining a control cell that does not express a recombinant opioid receptor; b) obtaining a test cell that is the same as the control cell except that it expresses a recombinant opioid receptor selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity; c) contacting the control cell and test cell with an amount of an opioid sufficient to exert a physiologic effect; d) separately measuring the physiologic effect of the composition on the control cell and test cell; and e) comparing the physiologic effect of the composition to the physiologic effect of the opioid, where determination of a physiologic effect of the composition is expressed relative to that of the opioid. 89. The method according to claim 88, where the composition is selected from the group consisting of synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, or media conditioned by cultured eukaryotic cells. 90. The method according to claim 88, where the opioid is selected from the group consisting of moφhine, methadone, etoφhine, levoφhanol, fentanyl, sufentanil, [D-Ala 2 ,MePhe 4 ,Gly(ol) 5 ]enkephalin (DAMGO), pentazocine, ethylketocyclazocine, bremazocine, spiradoline, [D-Ser ,Leu 5 ]enkephalin-Thr 6 (DSLET), Met-enkephalin, Leu-enkephalin, β-endoφhin, dynoφhin A, dynoφhin B, or α-neoendoφhin. 91. The method according to claim 88, where the physiological effect is measured by changes in the levels of neuroendocrine hormones. 92. The hormone according to claim 91, where the hormone is selected from the group consisting of prolactin, growth hormone, gonadotropin-rel easing hormone, adrenocorticotropin, corticotropin-releasing factor, luteinizing hormone, follicle stimulating hormone, testosterone or cortisol. 93. The method according to claim 88, where the physiological effect is measured by changes in the levels of neurotransmitters. 94. The neurotransmitter according to claim 93, where the neurotransmitter is acetylcholine or dopamine. 95. The method according to claim 88, where the homolog is a human homolog. 96. A method of screening compositions for opioid activity comprising the steps of a) obtaining a control polypeptide that is not a recombinant opioid receptor; b) obtaining a test polypeptide that is a recombinant opioid receptor selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR- 1 opioid-binding activity; c) contacting a composition with the control polypeptide and the test polypeptide; d) contacting the test polypeptide with an amount of an opioid sufficient to measurably bind the test polypeptide; c) measuring the binding of the composition and the opioid; and e) comparing test polypeptide binding of the composition to that of the opioid, where determination of binding of the composition is expressed relative to that of the opioid. 97. The method according to claim 96, where the composition is selected from the group consisting of synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, or media conditioned by cultured eukaryotic cells. 98. The method according to claim 96 where the homolog is a human homolog. 99. A method of screening compositions for differential opioid activity comprising the steps of a) obtaining a first test polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, and contacting it with a composition; b) obtaining a second test polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity; c) measuring the binding of the composition to the first and second test polypeptides; and d) comparing the binding of the composition and the first test polypeptide to that of the second test polypeptide where differential activity is expressed as a ratio of the two binding affinities. 100. The method according to claim 99, where the composition is selected from the group consisting of synthetic combinatorial libraries of small molecule ligands, eukaryotic whole cell lysates or extracts, or media conditioned by cultured eukaryotic cells. 101. The method according to claim 99, where the homolog is a human homolog. 102. A non-human animal in which one or both endogenous MOR-1 alleles has been altered by homologous recombination with an exogenously introduced nucleic acid. 103. A non-human transgenic animal carrying a transgene comprising a nucleic acid that encodes a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity. 104. The transgenic animal according to claim 103, where the homolog is a human homolog. 105. A method for regulating moφhine analgesia in a subject comprising altering the amount of MOR-1 polypeptide fragment activity by a) administering antigen binding fragments to a subject in an amount and a duration sufficient to regulate moφhine analgesia; or b) administering agonists to a subject in an amount and a duration sufficient to regulate moφhine analgesia; or c) administering antagonists to a subject in an amount and a duration sufficient to regulate moφhine analgesia; or d) administering small molecule ligands to a subject in an amount and a duration sufficient to regulate moφhine analgesia; or e) administering a DNA plasmid vector containing a nucleic acid encoding a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, thereby expressing an MOR-1 splice variant polypeptide fragment in a subject in an amount and a duration sufficient to regulate moφhine analgesia; or f) administering an antisense nucleic acid corresponding to a nucleic acid comprising a polypeptide encoding a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, to a subject in an amount and a duration sufficient to regulate moφhine analgesia, and wherein the antigen binding fragment, agonist, antagonist or small molecule ligand is directed to a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity. 106. The method according to claim 105, where the homolog is a human homolog. 107. A method for regulating body weight in a subject comprising altering the level of MOR-1 polypeptide fragment activity by a) administering antigen binding fragments to a subject in an amount and a duration sufficient to regulate body weight; or b) administering agonists to a subject in an amount and a duration sufficient to regulate body weight; or c) administering antagonists to a subject in an amount and a duration sufficient to regulate body weight; or d) administering small molecule ligands to a subject in an amount and a duration sufficient to regulate body weight; or e) administering a DNA plasmid vector containing a nucleic acid encoding a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, thereby expressing an MOR-1 splice variant polypeptide fragment in a subject in an amount and a duration sufficient to regulate body weight; or f) administering an antisense nucleic acid corresponding to a nucleic acid encoding a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity, to a subject in an amount and a duration sufficient to regulate body weight. and wherein the antigen binding fragment, agonist, antagonist or small molecule ligand is directed to a polypeptide selected from the group consisting of an MOR-1 splice variant polypeptide fragment or a homolog thereof or a polypeptide fragment thereof retaining MOR-1 opioid-binding activity. 108. The method according to claim 107, where the homolog is a human homolog. 109. The method, according to claim 105 or 107, where the agonist is moφhine, methadone, etoφhine, levoφhanol, fentanyl, sufentanil, [D- Ala 2 ,MePhe 4 ,Gly(ol) 5 ]enkephalin (DAMGO), butoφhanol, naloxone, naltrexone, D-Phe-Cys-Tyr-D-Tφ-Orn-Thr-Pen-Thr-NH 2 (CTOP), diprenoφhine, β- funaltrexamine, naloxonazine, naloφhine, pentazocine, nalbuphine, benzoylhydrazone, bremazocine, ethylketocyclazocine, U50488, U69593 spiradoline, naltrindole, [D-Pen 2 ,D-Pen 5 ]enkephalin (DPDPE), [D- Ala 2 ,Glu 4 ]deltoφhin, [D-Ser 2 ,Leu 5 ]enkephalin-Thr 6 (DSLET), Met-enkephalin, Leu-enkephalin, β-endoφhin, dynoφhin A, dynoφhin B, or α-neoendoφhin. 110. The method, according to claim 105 or 107, where the antagonist is moφhine, methadone, etoφhine, levoφhanol, fentanyl, sufentanil, [D- Ala 2 ,MePhe 4 ,Gly(ol) 5 ]enkephalin (DAMGO), butoφhanol, naloxone, naltrexone, D-Phe-Cys-Tyr-D-Tφ-Orn-Thr-Pen-Thr-NH 2 (CTOP), diprenoφhine, β- funaltrexamine, naloxonazine, naloφhine, pentazocine, nalbuphine, benzoylhydrazone, bremazocine, ethylketocyclazocine, U50488, U69593 spiradoline, naltrindole, [D-Pen 2 ,D-Pen 5 ]enkephalin (DPDPE), [D- Ala 2 ,Glu 4 ]deltoφhin, [D-Ser 2 ,Leu 5 ]enkephalin-Thr 6 (DSLET), Met-enkephalin, Leu-enkephalin, β-endoφhin, dynoφhin A, dynoφhin B, or α-neoendoφhin. 111. A method for diagnosing an MOR-1 splice variant-associated pharmacological abnormality, comprising measuring the amount of variant activity or tissue distribution thereof in a subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a pharmacological defect. 112. The method according to claim 111, where the disorder is a heritable disorder. 113. A method for diagnosing an MOR-1 splice variant-associated disorder of the neuroendocrine system, comprising measuring the amount of variant activity or tissue distribution in a subject and comparing that activity or tissue distribution to a control sample, wherein a difference in the amount of activity or tissue distribution correlates with the presence of a defect within the neuroendocrine system. 114. The method according to claim 113 where the disorder is a heritable disorder. 115. A method for generating antigen binding fragments specific for an MOR-1 splice variant polypeptide fragment or a homolog thereof or an MOR-1 polypeptide fragment.

Inventors: PAN YING-XIAN, PASTERNAK GAVRIL, PAN, YING-XIAN, PASTERNAK, GAVRIL
Applicants: PAN YING XIAN, PASTERNAK GAVRIL, SLOAN KETTERING INST CANCER, MEMORIAL SLOAN-KETTERING CANCER CENTER, PAN, YING-XIAN, PASTERNAK, GAVRIL
Application year: 1999
Main classification: C07K14
IPC codes: A61K38, C07K14